Chemically Modified iRNA Agents for Sustained ApoB Silencing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for reducing apolipoprotein B levels are inadequate in effectively treating lipid-related disorders such as atherosclerosis, as they only achieve moderate downregulation of ApoB and do not provide sustained reduction of serum cholesterol and triglyceride levels.

Innovation Solution

Administration of specific iRNA agents that silence the ApoB gene by targeting its mRNA with chemically modified oligonucleotides, including dsRNA and siRNA, which are designed to reduce ApoB mRNA and protein expression in cells, thereby decreasing lipid levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antisense therapy is used to reduce ApoB levels, then ApoB downregulation is achieved, but the reduction is only moderate and not sustained

Engineering Contradiction:

ImproveApoB reduction efficacyVSAvoidTreatment effectiveness

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the molecular parameters of the therapeutic agent by using chemically modified oligonucleotides (such as 2'-O-methyl modifications, phosphorothioate backbones) instead of conventional antisense oligonucleotides. These parameter changes enhance nuclease resistance, improve cellular uptake, and increase binding affinity to ApoB mRNA, resulting in more potent and sustained ApoB downregulation compared to moderate reduction achieved by standard antisense therapy.

Inventive Principle:

Principle #35Parameter changes

2Duration of action of moving object

If conventional therapies are used to treat lipid-related disorders, then treatment is provided, but sustained reduction of serum cholesterol and triglyceride levels is not achieved

Engineering Contradiction:

ImproveDuration of ApoB reductionVSAvoidLipid level control

Core Design Contradiction:

Duration of action of moving objectVSReliability

Solution Approach 1:

The chemically modified oligonucleotide therapy enables continuous and sustained suppression of ApoB expression by protecting the therapeutic agent from degradation by nucleases in the bloodstream and cellular environments. The modifications (e.g., phosphorothioate linkages, 2'-O-methyl ribose) create a stable complex that maintains prolonged contact with ApoB mRNA, ensuring continuous gene silencing and sustained reduction of serum cholesterol and triglyceride levels over extended treatment periods.

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The iRNA agents achieve significant reduction of ApoB mRNA and protein levels in human cells and mouse models, demonstrating a more effective approach to treating lipid-related disorders by providing sustained lowering of serum cholesterol and triglycerides.

Implementation Method 1

RNA interference or 'RNAi' is a term initially coined by Fire and co-workers to describe the observation that double-stranded RNA (dsRNA) can block gene expression when it is introduced into worms

Methodology Applied

Scientific EffectRNA interference (RNAi):

Implementation Method 2

Short dsRNA directs gene-specific, post-transcriptional silencing in many organisms, including vertebrates

Methodology Applied

Scientific EffectBase pairing:

Data Source

PatentUS8188061B2RNAi modulation of APOB and uses thereof

Publication Date: 2012.05.29 ALNYLAM PHARMACEUTICALS INC

AI summary

The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.